Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
An announcement from Allarity Therapeutics ( (ALLR) ) is now available.
On June 30, 2025, Alexander Epshinsky resigned as the Chief Financial Officer of Allarity Therapeutics, Inc., with no disagreements regarding company operations. Subsequently, on July 1, 2025, Jeffrey S. Ervin was appointed as the new part-time CFO. Ervin brings experience from his previous roles, including as CEO of Sanaregen Vision Therapeutics and IMAC Holdings. His employment agreement includes a $175,000 annual salary and severance pay in case of a change-of-control termination.
Spark’s Take on ALLR Stock
According to Spark, TipRanks’ AI Analyst, ALLR is a Underperform.
Allarity Therapeutics’ overall stock score is low due to significant financial challenges, including no revenue and consistent operational losses. Technical analysis shows a bearish trend with neutral momentum indicators, while valuation metrics are unfavorable with a negative P/E ratio and no dividend yield. These factors collectively suggest a high-risk investment with limited current appeal.
To see Spark’s full report on ALLR stock, click here.
More about Allarity Therapeutics
Allarity Therapeutics, Inc. operates in the biopharmaceutical industry, focusing on the development and commercialization of targeted cancer therapies.
Average Trading Volume: 766,826
Technical Sentiment Signal: Sell
Current Market Cap: $15.23M
For detailed information about ALLR stock, go to TipRanks’ Stock Analysis page.